Semaglutide 2.0 mg once-weekly dose schedules and new pen-injector compared in Type 2 Diabetes

For individuals managing Type 2 Diabetes (T2D), optimizing glycemic control and patient adherence remains a critical challenge. Glucagon-like peptide-1 receptor agonists (GLP-1R agonists) like semaglutide have revolutionized T2D treatment, but there's ongoing research to refine dosing strategies and delivery methods. Current semaglutide formulations typically escalate to 1.0 mg or 1.7 mg weekly. This study addresses the need to evaluate higher doses, specifically 2.0 mg once weekly, and to determine if different initial dose escalation schedules can improve tolerability or efficacy, alongside introducing a new pen-injector for enhanced patient experience.

The SUSTAIN SWITCH study is a randomized clinical trial comparing two dose schedules of semaglutide in Type 2 Diabetes patients previously treated with a GLP-1R agonist-like medicine. Participants will receive semaglutide once weekly via subcutaneous injection, alongside their existing oral diabetes medications (excluding semaglutide). Patients will be randomized to either a 0.25 mg or 0.50 mg starting dose, with gradual escalation to a final dose of 2.0 mg. The study duration is approximately 24 weeks, involving 9 in-person visits and 1 phone call. Blood samples will be taken at 9 visits, and eye examinations at 2 visits. A new pen-injector will be used once the 2.0 mg dose is reached.

This abstract describes the protocol for the SUSTAIN SWITCH study, a clinical trial designed to compare two semaglutide dose escalation schedules and evaluate a new pen-injector. As a study design document, it outlines the methodology and objectives but does not present any results or findings. The trial is active but not yet completed, meaning no data on efficacy, safety, or patient outcomes are available at this stage. Therefore, no specific numerical outcomes, p-values, or fold-changes can be reported from this abstract.